Ado-trastuzumab emtansine is named as an intervention in 21 current clinical trials in our China, USA, Spain, Italy, South Korea, France, Belgium, Taiwan, Australia, UK, Germany, Mexico, Israel, Canada, Japan, Denmark, Poland, Brazil, Singapore, Czechia, Portugal, Netherlands, Turkey, Switzerland, Norway, Austria, Egypt, Ireland, India and Sweden registers. 7 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Daiichi Sankyo (2). The most-studied condition is HER2-positive Breast Cancer.
Of the three regulators tracked here, the first to approve Ado-trastuzumab emtansine was the US, on 22 Feb 2013.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
| Study | Phase | Status | Lead sponsor | Registers |
|---|
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| HER2-positive Breast Cancer | 8 |
| Breast Cancer | 3 |
| HER2-Positive Primary Breast Cancer | 1 |
| Residual Invasive Breast Cancer | 1 |
| Metastatic Breast Cancer | 1 |
| Metastatic Gastric Adenocarcinoma | 1 |
| Gastroesophageal Junction Adenocarcinoma | 1 |
| Esophageal Adenocarcinoma | 1 |
| Neoplasm Metastasis | 1 |
| HER2 Mutant Non-small Cell Lung Cancer | 1 |
| HER2-positive Metastatic Breast Cancer | 1 |
| HER2 Gene Mutation | 1 |
| HER2 Amplification | 1 |
| Advanced Solid Tumor | 1 |
| Locally Advanced Solid Tumor | 1 |
| Metastatic Solid Tumor | 1 |
| Platinum-resistant Ovarian Cancer | 1 |
| Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants | 1 |
| Advanced or Metastatic Pancreatic Adenocarcinoma | 1 |
| Advanced or Metastatic Breast Cancer (BC) | 1 |
| Breast Cancer Invasive | 1 |
| Advanced Lymphoma | 1 |
| Advanced Malignant Solid Neoplasm | 1 |
| Bladder Carcinoma | 1 |
| Breast Carcinoma | 1 |
| Metastatic Salivary Gland Carcinoma | 1 |
| Recurrent Salivary Gland Carcinoma | 1 |
| Stage III Major Salivary Gland Cancer AJCC v8 | 1 |
| Stage IV Major Salivary Gland Cancer AJCC v8 | 1 |
| Anatomic Stage II Breast Cancer AJCC v8 | 1 |
| Anatomic Stage IIA Breast Cancer AJCC v8 | 1 |
| Anatomic Stage IIB Breast Cancer AJCC v8 | 1 |
| Anatomic Stage IIIA Breast Cancer AJCC v8 | 1 |
| Lead sponsor | Trials |
|---|---|
| Daiichi Sankyo | 2 |
| Sichuan Baili Pharmaceutical Co., Ltd | 2 |
| Boehringer Ingelheim | 1 |
| Genentech, Inc | 1 |
| Hoffmann-La Roche | 1 |
| Seagen, a wholly owned subsidiary of Pfizer | 1 |
| Enliven Therapeutics | 1 |
| Ascendis Pharma Oncology Division A/S | 1 |
| DualityBio Inc | 1 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd | 1 |
| Shanghai JMT-Bio Inc | 1 |
| Fudan University | 1 |
| Shanghai Jiao Tong University School of Medicine | 1 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd | 1 |
| GeneQuantum Healthcare (Suzhou) Co., Ltd | 1 |
+ 4 more sponsors in the trial list above.
A trial with sites in more than one country appears in each of those registers.
21 current trials in our China, USA, Spain, Italy, South Korea, France, Belgium, Taiwan, Australia, UK, Germany, Mexico, Israel, Canada, Japan, Denmark, Poland, Brazil, Singapore, Czechia, Portugal, Netherlands, Turkey, Switzerland, Norway, Austria, Egypt, Ireland, India and Sweden registers name Ado-trastuzumab emtansine (also registered as T-DM1) as a drug or biological intervention, as of the registry sync on 6 October 2026. Completed and withdrawn studies are not counted.
Yes. 7 of the 21 trials are recruiting: 5 with sites in China, 1 with sites in USA, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in South Korea, 1 with sites in France, 1 with sites in Belgium, 1 with sites in UK, 1 with sites in Germany, 1 with sites in Mexico, 1 with sites in Israel and 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Daiichi Sankyo (2), Sichuan Baili Pharmaceutical Co., Ltd (2), Boehringer Ingelheim (1) and Genentech, Inc (1), among 19 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ado-trastuzumab emtansine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ado-trastuzumab emtansine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ado-trastuzumab emtansine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 6 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.
